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Identification of a Potential Cardiac
Antifibrotic Mechanism of Torasemide
in Patients With Chronic Heart Failure
Begoña Lo´pez, PHD,* Arantxa Gonza´lez, PHD,* Javier Beaumont, PHD,*
Ramo´n Querejeta, MD, PHD,† Mariano Larman, MD,‡ Javier Dı´ez, MD, PHD*§
Pamplona and San Sebastián, Spain
Objectives This study sought to investigate whether torasemide inhibits the enzyme involved in the myocardial extracellular
generation of collagen type I molecules (i.e., procollagen type I carboxy-terminal proteinase [PCP]).
Background Torasemide has been reported to reduce myocardial fibrosis in patients with chronic heart failure (HF).
Methods Chronic HF patients received either 10 to 20 mg/day oral torasemide (n  11) or 20 to 40 mg/day oral furo-
semide (n  11) in addition to their standard HF therapy. At baseline and after 8 months from randomization,
right septal endomyocardial biopsies were obtained to analyze the expression of PCP by Western blot and the
deposition of collagen fibers (collagen volume fraction [CVF]) with an automated image analysis system. The
carboxy-terminal propeptide of procollagen type I (PICP) released as a result of the action of PCP on procollagen
type I was measured in serum by radioimmunoassay.
Results The ratio of PCP active form to PCP zymogen, an index of PCP activation, decreased (p  0.05) in torasemide-
treated patients and remained unchanged in furosemide-treated patients. A reduction (p  0.01) in both CVF
and PICP was observed in torasemide-treated but not in furosemide-treated patients. Changes in PCP activation
were positively correlated (p 0.001) with changes in CVF and changes in PICP in patients receiving torasemide.
Conclusions These findings suggest the hypothesis that the ability of torasemide to reduce myocardial fibrosis in chronic HF
patients is related to a decreased PCP activation. Further studies are required to ascertain whether PCP may
represent a new target for antifibrotic strategies in chronic HF. (J Am Coll Cardiol 2007;50:859–67) © 2007 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.080C
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fyocardial fibrosis has been proposed as a major determi-
ant of altered left ventricular function leading to chronic
eart failure (HF) in patients with cardiac diseases (1,2). It
as been proposed that myocardial fibrosis is primarily
he result of the uncoupling between increased synthesis
nd unchanged or decreased degradation of collagen type
fibers (3,4).
Collagen type I is synthesized and secreted by fibroblasts
s procollagen type I precursor having amino-terminal and
arboxy-terminal propeptides that are cleaved to yield the
riple helical monomers (Fig. 1) (5). The enzyme procolla-
en type I carboxy-terminal proteinase (PCP) is a neutral,
rom the *Division of Cardiovascular Sciences, Centre for Applied Medical Research,
niversity of Navarra, Pamplona, Spain; †Division of Cardiology, Donostia Univer-
ity Hospital, San Sebastia´n, Spain; ‡Division of Hemodynamics, Guipuzcoa Poly-
linics, San Sebastia´n, Spain; and the §Department of Cardiology and Cardiovascular
urgery, University Clinic, University of Navarra, Pamplona, Spain. Partially funded
y the Red Tema´tica de Investigacio´n Cardiovascular (RECAVA), Ministry of
ealth, Spain, and by the arrangement between the FIMA and UTE-CIMA project.i
Manuscript received February 20, 2007; revised manuscript received April 25,
007, accepted April 30, 2007.a2-dependent proteinase responsible for the cleavage of
he carboxy-terminal propeptide of procollagen type I
PICP) that is further released to the blood stream (Fig. 1)
6,7). The hydrolytic activity of PCP is enhanced up to
0-fold by a 55-kDa glycoprotein enhancer (PCPE) and by
ts 36- and 34-kDa PCPE proteolytic fragments (Fig. 1)
8,9). In addition, PCP stimulates extracellular activation of
he enzyme lysyl oxidase that controls the formation of
ovalent cross-links between collagen type I molecules to
orm collagen type I fibrils (Fig. 1). In fibrogenic cells, the
nzyme is primarily secreted as a 112-kDa inactive zymogen
ith a proregion that is removed to yield the 96-kDa active
orm (10).
We reported recently that long-term treatment with differ-
nt loop diuretics may have a variable impact on myocardial
brosis and collagen type I biosynthesis in chronic HF patients
11). In fact, although torasemide-treated patients showed
ecreased myocardial collagen accumulation and serum PICP,
urosemide-treated patients did not. In addition, a greater
mprovement of New York Heart Association functional
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Fibrosis and Heart Failure August 28, 2007:859–67class and of parameters assessing
cardiac function was observed in
torasemide-treated patients than
in those treated with furosemide.
We thus have explored whether
torasemide alters the expression
of the PCP/PCPE system and
this, in turn, results in reduced
PCP activity and decreased col-
lagen deposition in the myocar-
dium of newly recruited chronic
HF patients. To evaluate this
possibility we studied changes in
myocardial PCP, PCPE, and
collagen volume fraction (CVF),
and serum PICP in HF patients
receiving either torasemide or fu-
rosemide. The effects of these
drugs on the synthesis of procol-
lagen type I precursor (i.e., 1
hain of procollagen type I messenger ribonucleic acid
mRNA]) and the degradation of collagen type I fibers (i.e.,
atrix metalloproteinase [MMP]-1 and tissue inhibitor
atrix metalloproteinase [TIMP]-1) were also analyzed.
ethods
atients and study protocols. This was an individually
andomized, open-label, parallel-group pilot study. All sub-
ects gave written, informed consent before participating in
he study. The investigation conformed to the principles
utlined in the Declaration of Helsinki. The study protocol
Figure 1 Generation of Collagen Type I Fibers
Schematic representation of the steps involved in the synthesis and processing of
collagen type I molecules. DNA  deoxyribonucleic acid; PCP  procollagen type I
carboxy-terminal proteinase; PCPE  procollagen type I carboxy-terminal proteinase
enhancer; PICP  carboxy-terminal propeptide of procollagen type I.
Abbreviations
and Acronyms
CVF  collagen volume
fraction
HF  heart failure
MMP  matrix
metalloproteinase
mRNA  messenger
ribonucleic acid
PCP  procollagen type I
carboxy-terminal proteinase
PCPE  procollagen type I
carboxy-terminal proteinase
enhancer
PICP  carboxy-terminal
propeptide of procollagen
type I
TIMP  tissue inhibitor of
matrix metalloproteinasebas approved by the Institutional Ethics Committee of the
onostia University Hospital.
The study population consisted of 22 white patients. All
atients were required to have a previous diagnosis of
hronic HF by the presence of a least 1 major and 2 minor
riteria of the Framingham study (12) during the last 6
onths. Whereas 80% of the patients enrolled had hyper-
ensive heart disease, the remaining 20% showed ischemic
eart disease. None of the patients had suffered from
revious myocardial infarction. A depressed ejection frac-
ion (0.40) was observed in 55% of patients.
Although all patients were clinically stable, they were
andomly assigned to receive either torasemide or furo-
emide in accordance with recent data (13). After random-
zation, 11 patients were assigned to torasemide 10 to 20 mg
aily (torasemide group) and 11 patients to furosemide 20
o 40 mg daily (furosemide group) for 8 months. The doses
ere used in accordance with current guidelines for
atients with chronic HF (14). Existing recommended
alt intake restriction (4 g/day) and concomitant HF med-
cations (i.e., an angiotensin-converting enzyme inhibitor,
r an angiotensin-receptor antagonist, and a beta-
drenergic blocker) were continued during the study (14).
one of the patients were treated with aldosterone antag-
nists. A number of studies, including endomyocardial
iopsy, were performed in each patient at enrollment
baseline) and 8 months after randomization.
A group of 12 normotensive subjects (7 men and 5
omen, mean age 56 years, range 39 to 72 years) were used
s control subjects for histomorphologic and biochemical
tudies. They were subjects with clinically presumed coro-
ary artery disease who were found to lack the disease at a
oronary angiography.
chocardiographic assessment. Two-dimensional echo-
ardiographic imaging, targeted M-mode recordings, and
oppler ultrasound measurements were obtained in each
atient as recommended (15). Left ventricular mass was
easured, and left ventricular mass index was calculated by
ividing left ventricular mass by body surface area. The
ollowing pulsed Doppler measurements were obtained:
aximum early transmitral velocity in diastole, maximum
ate transmitral velocity in diastole, the deceleration time of
he early mitral filling wave, and isovolumic relaxation time.
jection fraction was calculated according to Quinones
t al. (16).
iochemical determinations. Venous blood samples were
rawn at 09:00 h in an upright position. Plasma aldosterone
as measured by radioimmunoassay using a commercial kit.
erum PICP was determined by radioimmunoassay accord-
ng to a method previously described (17).
istomorphologic and immunohistochemical studies.
hree transvenous endomyocardial biopsies were taken
rom the middle area of the interventricular septum with a
ioptome Cordis 96 cm (7-F) under fluoroscopic guidance
fter angiographic examination. The CVF was determined
y quantitative morphometry with an automated image
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August 28, 2007:859–67 Fibrosis and Heart Failurenalysis system in sections stained with collagen-specific
icrosirius red, as previously reported (18).
Immunohistochemical analysis for PCP and PCPE was
erformed on formalin-fixed and paraffin-embedded sec-
ions. Immunohistochemical staining was performed by the
vidin peroxidase-labeled dextran polymer method. Positive
taining was visualized with DAB Plus (Boehringer Mann-
eim Corp., Indianapolis, Indiana), and tissues were coun-
erstained with Harris hematoxylin (Sigma, St. Louis,
issouri). A mouse monoclonal antibody against PCP
dilution 1:100; R&D Systems, Abingdom, England) and
CPE (dilution 1:100; R&D Systems) was used as the
rimary antibody.
estern blot studies. A 5-g sample of total protein
btained from transvenous endomyocardial biopsies was
rocessed for Western blot as recently described (19).
pecific rabbit polyclonal antibodies against PCP (R&D
ystems, specificity 95%), PCPE (R&D Systems; specificity
00%), MMP-1 (Oncogene, Cambridge, Massachusetts;
pecificity 100%) and TIMP-1 (Chemicon, Hofheim, Ger-
any; specificity 95%) were incubated at dilutions of 1:500,
:100, 1:2,000, and 1:200, respectively. Bands were detected
y peroxidase-conjugated secondary antibodies (Amersham
iosciences, Barcelona, Spain) and visualized with the
CL-Plus chemiluminescence system (Amersham Bio-
ciences). Autoradiograms were analyzed using an auto-
atic densitometer (Molecular Imager FX, Bio-Rad, Bar-
elona, Spain). The blots were also probed with a
onoclonal beta-actin antibody (Sigma) as a control for
oading. Data are expressed as arbitrary densitometric units
elative to beta-actin expression.
everse transcriptase-polymerase chain reaction (RT-
CR) study. The mRNA levels of the 1 chain of
rocollagen type I were analyzed by real-time quantita-
ive RT-PCR as recently described (20). Reverse tran-
cription was performed with 200 g of total RNA by
sing Superscript III reverse transcriptase (Invitrogen,
ugene, Oregon). Real-time PCR was performed with
n ABI PRISM 7000 Sequence Detection System ac-
ording to the manufacturer’s recommendations (Applied
iosystems, Madrid, Spain) by using specific TaqMan
GB fluorescent probes for human mRNA of the 1
hain of procollagen type I (Hs00176329), and a specific
aqMan MGB fluorescent probe for human constitutive
8S ribosomal RNA as endogenous control. Data are ex-
ressed as arbitrary units relative to 18S ribosomal RNA.
tatistical analysis. Differences in parameters between
ormotensive controls and the whole group of HF patients
t baseline and between the 2 groups of HF patients at
aseline and after treatment (absolute values and deltas)
ere tested using a Student t test for unpaired data once
ormality was shown (Shapiro-Wilks test); otherwise, a
onparametric test (Mann-Whitney U test) was used. Dif-
erences in parameters before and after treatment within
ach group of patients were tested by a Student t test for
aired data once normality was shown (Shapiro-Wilks test); vtherwise, a nonparametric test (Wilcoxon test) was used.
he correlation between continuously distributed variables
as tested by univariate regression analysis and bivariate
ssociation (Spearman coefficient). Data are expressed as
ean value  SEM. A value of p  0.05 was considered
tatistically significant.
esults
aseline characteristics. Baseline clinical and echocar-
iographic characteristics of the 2 groups of patients are
resented in the Table 1. No significant differences were
bserved between the groups in the parameters tested.
As shown in Figure 2, 2 PCP bands of 112 and 96 kDa
orresponding to zymogen and active form, respectively, were
dentified in myocardial samples from all patients. In addition,
he 55-kDa full-length and the 36-kDa proteolytic fragment of
CPE were also detected in all samples (Fig. 3). Figure 4
hows that although PCP and PCPE were mostly expressed in
broblasts and areas of interstitial and perivascular fibrosis, these
olecules also were present in cardiomyocytes.
Myocardial parameters evaluated in the normotensive group
nd the whole group of HF patients are presented in Table 2.
s expected, values related to collagen expression and deposi-
ion, as well as PICP values, were higher in patients than in
ormotensive subjects. In addition, PCP zymogen was de-
reased and PCP activation, assessed as the ratio between its
ctive form and its zymogen, and 36-kDa PCPE were in-
reased in HF patients compared with normotensive subjects.
No significant differences were found between the 2
roups of patients in the baseline values of parameters
ssessing myocardial fibrosis and collagen type I synthesis
nd degradation (Table 3). The PCP activation did tend to
e higher in the torasemide group (2.59  0.21) than in the
urosemide group (2.14  0.16), but the difference did not
each statistical significance. A positive correlation (r 
.687, p  0.001) was found between plasma aldosterone
nd PCP activation in all patients (Fig. 5).
ffects of treatment. GENERAL ASPECTS. Eight months
fter randomization, patients in the torasemide group (n
11) and the furosemide group (n  11) received mean
aily dosages of 10.9  0.6 mg and 34.5  3.8 mg of
hese agents, respectively. Baseline medications other
han loop diuretics were maintained unchanged during
he treatment period in the 2 groups of patients. No
dverse effects occurred during the study in either group.
he frequency of complications (including hospitaliza-
ions and exacerbations of HF) was similar in the 2
roups (data not shown).
LINICAL AND ECHOCARDIOGRAPHIC DATA. As shown in
able 1, the changes in body weight and blood pressure
ere similar in the 2 groups of patients. The values of left
entricular end-diastolic volume showed a nonsignificant
rend toward a decrease in torasemide-treated but not in
urosemide-treated patients (Table 1). The values of left
entricular ejection fraction showed a nonsignificant trend
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Fibrosis and Heart Failure August 28, 2007:859–67oward an increase in torasemide-treated but not
urosemide-treated patients (Table 1). The number of
atients showing improvement of at least 1 grade in New
ork Heart Association functional class was greater
p  0.01) in the torasemide group than in the furosemide
roup.
YOCARDIAL FIBROSIS. Although CVF decreased (p 
.01) in the torasemide-treated patients, it remained un-
hanged in furosemide-treated patients (Table 3). In addition,
VF was lower (p 0.01) in torasemide-treated patients than
n furosemide-treated patients. Furthermore, the delta for this
arameter was also different between the 2 groups (torasemide-
reated patients 43.20  6.40%, furosemide-treated patients
Effects of Treatment on Clinical Parameters Assin the 2 Groups of Patients With Chronic Heart
Table 1 Effects of Treatment on Clinical Pain the 2 Groups of Patients With Ch
Furosemide
Parameters Baseline
Age, yrs 62 4
Gender, M/F 9/2
Body weight, kg 82.2 3.5
Causes of HF, n
HHD 9
IHD 2
Types of HF, n
EF 0.40 4
EF 0.40 7
Medications, n
ACEI or ARA 11
Beta-blocker 11
Digoxin 3
Diuretic
Furosemide 11
Torasemide 0
Hct  amiloride 1
SBP, mm Hg 139 5
DBP, mm Hg 86 3
LVMI, g/m2 162 18
RWT 0.35 0.02
LVEDD, mm 60.2 2.3
VE/VA 1.29 0.49
IVRT, ms 110 8
DT, ms 210 24
EF 0.37 0.03
NYHA functional class,† n
I —
II 2
II 8
IV 1
Aldosterone, pg/ml 125 34
Data are expressed as the mean value SEM or number of patients. *
in NYHA functional class 8 months after randomization.
ACEI angiotensin-converting enzyme inhibitor; ARA angiotensin
time; EF  ejection fraction; Hct  hydrochlorothiazide; HF  heart fa
 isovolumic relaxation time; LVEDD  left ventricular end-diastoli
Association; RWT relative wall thickness; SBP systolic blood press
transmitral velocity in diastole.4.11  7.30%, p  0.05). sARAMETERS RELATED TO COLLAGEN TYPE I SYNTHESIS
ND DEGRADATION. As shown in Table 3, the expression
f 1(I) mRNA decreased (p  0.05) to a similar extent
n the 2 groups of treated patients. Whereas administra-
ion of torasemide was associated with a reduction (p 
.01) in serum PICP, this parameter did not change in
he furosemide group (Table 3). In addition, serum PICP
easured 8 months after randomization was lower (p 
.01) in the torasemide group than in the furosemide
roup. The delta for this parameter was different between
he 2 groups (torasemide-treated patients 19.30  3.30%,
urosemide-treated patients 4.12  6.40%, p  0.05).
A positive correlation was found between changes in
dre
ers Assessed
Heart Failure
Torasemide Group
eatment Baseline Treatment
66 3
8/3
6 4.1 84.3 3.6 84.3 3.6
8
3
6
5
11 11 11
11 11 11
3 4 4
11 0 0
0 11 11
1 0 0
2 4* 147 4 127 3*
4 2* 91 3 76 2*
8 5 160 15 156 10
3 0.01 0.34 0.03 0.36 0.03
4 1.5 60.8 2.9 55.9 3.1
8 0.31 1.36 0.26 1.27 0.27
0 9 107 5 112 7
3 29 199 20 218 23
8 0.04 0.39 0.04 0.42 0.03
0 — 0
7 5 9
3 5 2
1 1 0
7 15 125 45 105 26
1 versus values at baseline in the same group. †p 0.01 for changes
ceptor antagonist; DBP diastolic blood pressure; DT deceleration
D  hypertensive heart disease; IHD  ischemic heart disease; IVRT
ter; LVMI  left ventricular mass index; NYHA  New York Heart
maximum late transmitral velocity in diastole; VEmaximum earlyesseFailu
ramet
ronic
Group
Tr
82.
12
7
15
0.3
59.
1.0
11
21
0.3
9
p 0.0
type I re
ilure; HH
c diame
ure; VAerum PICP and changes in CVF (r  0.692, p  0 .01) in
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August 28, 2007:859–67 Fibrosis and Heart Failureorasemide-treated patients (Fig. 6). No significant changes
n either MMP-1 or TIMP-1 were observed in the 2 groups
ith treatment (Table 3).
CP AND PCPE EXPRESSION. The expression of both PCP
ymogen and PCP active form increased (p  0.05) in the
urosemide group, but remained unchanged in the to-
asemide group (Table 3, Fig. 2). Whereas PCP activation
emained unchanged in furosemide-treated patients (1.96
.16), it decreased (p 0.05) in torasemide-treated patients
2.14  0.19).
The expression of full-length PCPE did not change with
reatment in either group of patients (Table 3, Fig. 3). The
6-kDa PCPE fragment decreased (p  0.05) in
orasemide-treated patients and remained unchanged in
urosemide-treated patients (Table 3, Fig. 3).
Figure 2 Western Blot Autoradiograms of PCP
Representative Western blot autoradiograms of myocardial PCP from 1 patient
semide (left), and 1 chronic heart failure patient at baseline and 8 months aft
Figure 3 Western Blot Autoradiograms of PCPE
Representative Western blot autoradiograms of myocardial PCPE from 1 patien
semide (left), and 1 chronic heart failure patient at baseline and 8 months aftChanges in PCP activation were positively correlated
ith both changes in CVF (r 0.876, p 0.001) (Fig. 7A)
nd changes in serum PICP (r  0.897, p  0.001) (Fig.
B) in torasemide-treated patients. In addition, a positive
orrelation (r  0.588, p  0.05) was found between final
alues of plasma aldosterone and the inhibition of PCP
ctivation in torasemide-treated patients. These correlations
ere not found in furosemide-treated patients. No other
orrelations were found among the remaining parameters
ested in this study.
iscussion
he main findings of this study are as follows: 1) 1(I)
RNA levels (an index of the synthesis of procollagen type
precursor) decreased to a similar extent in torasemide-
hronic heart failure at baseline and 8 months after randomization to furo-
domization to torasemide (right). Abbreviations as in Figure 1.
chronic heart failure at baseline and 8 months after randomization to furo-
domization to torasemide (right). Abbreviations as in Figure 1.with c
er rant with
er ran
t
p
a
w
t
t
f
P
p
i
e
b
t
h
m
t
a
a
p
fi
n
a
fi
a
p
c
CNo
D
d
m
864 Lo´pez et al. JACC Vol. 50, No. 9, 2007
Fibrosis and Heart Failure August 28, 2007:859–67reated patients with chronic HF as in furosemide-treated
atients; 2) although the expression of both PCP zymogen
nd active form increased in chronic HF patients treated
ith furosemide, they did not change after treatment with
orasemide; 3) the activation of PCP decreased in
orasemide-treated patients, but remained unchanged in
urosemide-treated patients; 4) the expression of 36-kDa
CPE fragment was reduced with treatment in chronic HF
atients receiving torasemide, whereas it remained unchanged
n patients receiving furosemide; and 5) no changes in the
xpression of full-length PCPE and the MMP-1/TIMP-1
alance were found in either group of chronic HF patients with
reatment. Collectively, these findings generate the working
ypothesis that the ability of torasemide to interfere with the
yocardial PCP/PCPE system may be one contributing factor
o its antifibrotic effect. Nevertheless, other mechanisms can
lso be involved in the antifibrotic effect of torasemide (e.g., its
bility to interfere with the direct trophic actions of the
rofibrotic factor angiotensin II) (21).
Although initially isolated from the medium of cultured
broblasts (22), PCP has been further characterized in a
umber of cell types (6,7). In this regard, we found that in
Figure 4 PCP and PCPE Expression
Histological sections of myocardial biopsy specimens from 1 patient with chronic h
were identified in brown and located mostly in areas of interstitial and perivascula
(B, D) Negative controls for the correspondent primary antibody omission. Magnifiddition to its localization in the interstitial space and
t
tbroblasts, PCP and PCPE are expressed in cardiomyocytes
s found in endomyocardial biopsy tissue obtained from
atients with chronic HF. We have shown recently that
ardiomyocytes from chronic HF patients express MMP-1
ailure. (A, C) Immunostaining for PCP and PCPE, respectively. These molecules
is (arrows). Positive staining also was seen in cardiomyocytes (arrowheads).
100. Abbreviations as in Figure 1.
linical and Cardiac Parameters Assessed inormotensive Subjects nd in the Whole Groupf Patient With Chronic H art Failure
Table 2
Clinical and Cardiac Parameters Assessed in
Normotensive Subjects and in the Whole Group
of Patients With Chronic Heart Failure
Parameters Normotensive Patients HF Patients
CVF, % 1.95 0.07 8.03 0.49*
1(I) mRNA, AU 37.5 7.4 163.8 21.4*
PCP zymogen, ADU 15,720 157 10,211 444*
PCP active form, ADU 22,916 542 23,860 1426
PCP activation 1.45 0.04 2.42 0.08
Full-length PCPE, ADU 0.32 0.03 0.35 0.03
36-kDa fragment PCPE, ADU 0.28 0.02 0.39 0.04*
PICP, g/l 82 8 144 6*
MMP-1, ADU 0.96 0.16 1.08 0.10
TIMP-1, ADU 1.16 0.21 1.02 0.07
ata are expressed as the mean value  SEM. *p  0.01 versus values in normotensive patients.
1(I) mRNA  1 chain of procollagen type I messenger ribonucleic acid; ADU  arbitrary
ensitometric units; AU  arbitrary units; CVF  collagen volume fraction; MMP  matrix
etalloproteinase; PCP  procollagen type I carboxy-terminal proteinase; PCPE  procollageneart f
r fibros
cationype I carboxy-terminal proteinase enhancer; PICP  carboxy-terminal propeptide of procollagen
ype I; TIMP  tissue inhibitor of matrix metalloproteinase.
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August 28, 2007:859–67 Fibrosis and Heart Failurend TIMP-1 that regulate collagen degradation (19).
herefore, because of the critical role that the PCP/PCPE
ystem plays in collagen type I synthesis and deposition, it is
ikely that in addition to fibroblasts, cardiomyocytes regulate
ollagen turnover in the failing human heart.
Activity of PCP can be regulated at 3 levels: 1) PCP
ymogen synthesis; 2) activation of PCP zymogen into PCP
ctive form; and 3) PCPE availability (8–10). In this regard,
hanges reported here in furosemide-treated patients at the
evel of PCP zymogen and active form would suggest that
he activity of the enzyme increased in these patients. In
upport of this possibility, we found that despite a decrease
n the availability of procollagen type I precursor, PICP and
VF did not change in furosemide-treated patients. On the
ther hand, changes found in patients receiving torasemide
t the level of PCP activation and 36-kDa PCPE fragment
Figure 5 Association Between
Aldosterone and PCP Activation
Positive correlation (y  0.004x  1.907) between plasma aldosterone and
activation of myocardial PCP (as assessed by the ratio of PCP active form to
PCP zymogen) in all patients with chronic heart failure. Abbreviations as in Fig-
ure 1.
Effects of Treatment on Parameters Related toType I Synth sis a d Degr dation Ass ssed in tHeart Failure
Table 3
Effects of Treatment on Parameters
Type I Synthesis and Degradation A
Heart Failure
Furosemide
Parameters Baseline
CVF, % 7.90 0.87
1(I) mRNA, AU 158 19
PCP zymogen, ADU 10,484 626
PCP active form, ADU 21,616 2,106
Full-length PCPE, ADU 0.37 0.04
36-kDa fragment PCPE, ADU 0.39 0.05
PICP, g/l 144 9
MMP-1, ADU 1.04 0.09
TIMP-1, ADU 0.96 0.09
Data are expressed as the mean value  SEM. *p  0.01 versus value
randomization in the furosemide group. ‡p  0.05.
Abbreviations as in Tables 1 and 2.ould suggest that PCP activity diminished with treatment
n these patients. This change in combination with a
iminished availability of procollagen type I precursor can
xplain the associated decrease in PICP and CVF observed
n torasemide-treated patients.
Because transforming growth factor-beta-1 has been
hown to stimulate the synthesis of both PCP zymogen and
ctive form in fibrogenic cell cultures (23,24), it is tempting
o speculate that this cytokine mediates up-regulation of
yocardial PCP associated with furosemide treatment.
owever, it has been reported that myocardial transforming
rowth factor-beta-1 decreases in Dahl high-salt HF rats
reated with furosemide (25). Thus, further studies are neces-
ary to clarify the effects of this compound on myocardial PCP.
Figure 6 Association Between PICP and CVF
Positive correlation (y  1.338x  18.73) between the reduction in serum
PICP and the reduction in myocardial collagen volume fraction (CVF) in patients
with chronic heart failure treated with torasemide. Abbreviations as in Figure 1.
ardial Fibrosis and CollagenG oups of Patients With Chronic
ted to Myocardial Fibrosis and Collagen
sed in the 2 Groups of Patients With Chronic
Torasemide Group
atment Baseline Treatment
9 0.59 8.29 0.52 4.24 0.24*†
7 10‡ 141 38 61 5‡
9 972‡ 10,229 1073 10,903 776
5 892‡ 24,485 1812 23,596 869
7 0.05 0.34 0.04 0.32 0.04
3 0.05 0.37 0.05 0.26 0.03‡
0 8 147 9 109 3*†
3 0.08 1.09 0.11 0.91 0.08
8 0.11 0.97 0.02 0.94 0.05
seline in the same group. †p  0.01 versus values after 8 months ofMyoche 2
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Fibrosis and Heart Failure August 28, 2007:859–67Aldosterone has been found to increase PCP activity and
CPE expression in cultured rat heart fibroblasts (26). In
ddition, it has been reported that aldosterone is involved in
nhanced PCPE mRNA expression seen in the remodeling
at myocardium after infarction (27). Interestingly, we
ound that a direct correlation exists between plasma aldo-
terone and PCP activation in chronic HF patients at
aseline, suggesting that the mineralocorticoid may regulate
CP activity in humans. In this regard, it is important to
emark that transcardiac extraction of aldosterone is reduced
Figure 7 Associations Among PCP
Activation and CVF and PICP
(A) Positive correlation (y  0.012x  27.48) between the reduction in PCP
activation (as assessed by the ratio of PCP active form to PCP zymogen) and
the reduction in myocardial CVF in patients with chronic heart failure treated
with torasemide. (B) Positive correlation (y  0.483x  9.979) between the
reduction in PCP activation (as assessed by the ratio of PCP active form to PCP
zymogen) and the reduction in serum PICP in patients with chronic HF treated
with torasemide. Abbreviations as in Figure 6.n chronic HF patients treated with torasemide (28) and bhat torasemide blocks the binding of the hormone to its
ineralocorticoid receptor (29). Our finding that a direct
orrelation exists between final values of aldosterone and
nhibition of PCP activation in torasemide-treated patients
ould suggest that the effects of torasemide on the myocar-
ial PCP/PCPE system in chronic HF patients are related
o this hormone.
Chemical inhibitors of PCP activity that are nontoxic to
ells in culture have been developed. These inhibitors are
ydroxamic acid derivatives that bind specifically the active
ite of the zinc (Zn) atom of PCP and therefore inhibit
nzyme activity (30). Of interest, whereas torasemide pos-
ess a Zn ligand residue, furosemide does not (31). Thus,
his chemical difference may add another mechanism
hrough which torasemide, but not furosemide, interferes
ith the PCP/PCPE system.
tudy limitations. This was a study involving a relatively
mall number of patients in whom diastolic function was not
xtensively investigated, but because of the nature of the
oals under investigation, this design is appropriate. In
ddition, it must be recognized that therapy with angiotensin-
onverting enzyme inhibitors or angiotensin-receptor antago-
ists that inhibit collagen synthesis and reduce fibrosis may
ave influenced the findings. Nevertheless, because there is
o available evidence showing that angiotensin II modifies
he PCP/PCPE system, it is reasonable to assume that the
ffect of torasemide on collagen type I synthesis is exerted
n top of the potential effects of angiotensin-converting
nzyme inhibitors and angiotensin-receptor antagonists.
Although no direct assessment of tissue PCP activity (i.e.,
ymography) was performed, serum PICP has been pro-
osed as a reliable index of collagen type I synthesis within
he human myocardium (32). Furthermore, the association
eported here between PCP activation and serum PICP
uggests that this peptide is a specific biomarker of the
ctivity of myocardial PCP in patients with chronic HF.
We have not studied the procollagen amino-proteinase
hat cleaves the amino-terminal propeptide of procollagen
ype I. However, impairment of amino-terminal propetide
s not incompatible with in vivo fibrillogenesis (33). In
ddition, in vitro studies have shown that collagen mono-
ers that retain the amino-propeptide are readily incorpo-
ated into growing fibrils along with normal monomers
34). In contrast, collagen type I monomers that retain
ICP are not incorporated into growing fibrils (34).
Because an excess of collagen type III deposition occurs in
he myocardium of HF patients, and picrosirius red binds to
ollagen molecules other than type I, such as type III, we
annot exclude the possibility that the changes in myocar-
ial collagen found in our patients also may be caused by
hanges in the deposition of fibril-forming collagen type III
olecules not investigated here. In addition, changes in colla-
en cross-linking and in other components of the extracellular
atrix (e.g., glycoproteins and proteoglycans) that have noteen studied here also may be altered in the failing heart.
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ur findings led us to hypothesize that the inhibition of the
CP/PCPE system may be one of the potential mecha-
isms involved in the ability of torasemide to repair myo-
ardial fibrosis in chronic HF patients. Further studies must
e conducted to identify the precise molecular pathways
hrough which torasemide inhibits the system in these
atients. Findings reported here set the stage for the
evelopment of antifibrotic cardiac therapies targeting the
CP/PCPE system.
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